JP2018521674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521674A5 JP2018521674A5 JP2018504991A JP2018504991A JP2018521674A5 JP 2018521674 A5 JP2018521674 A5 JP 2018521674A5 JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018521674 A5 JP2018521674 A5 JP 2018521674A5
- Authority
- JP
- Japan
- Prior art keywords
- encoding
- gene
- promoter
- propionate
- gene sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 33
- 241000894006 Bacteria Species 0.000 claims 27
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 18
- 108090000790 Enzymes Proteins 0.000 claims 11
- 102000004190 Enzymes Human genes 0.000 claims 10
- 230000001580 bacterial effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 230000001925 catabolic effect Effects 0.000 claims 7
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 230000015556 catabolic process Effects 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000003694 methylmalonic acidemia Diseases 0.000 claims 2
- 201000008152 organic acidemia Diseases 0.000 claims 2
- 201000004012 propionic acidemia Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims 1
- 102000057234 Acyl transferases Human genes 0.000 claims 1
- 108700016155 Acyl transferases Proteins 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241000194036 Lactococcus Species 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 101150036991 pccB gene Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199445P | 2015-07-31 | 2015-07-31 | |
| US62/199,445 | 2015-07-31 | ||
| US201662336338P | 2016-05-13 | 2016-05-13 | |
| US62/336,338 | 2016-05-13 | ||
| USPCT/US2016/032565 | 2016-05-13 | ||
| PCT/US2016/032565 WO2016183532A1 (en) | 2015-05-13 | 2016-05-13 | Bacteria engineered to treat a disease or disorder |
| US201662341320P | 2016-05-25 | 2016-05-25 | |
| US62/341,320 | 2016-05-25 | ||
| USPCT/US2016/037098 | 2016-06-10 | ||
| PCT/US2016/037098 WO2016201380A1 (en) | 2015-06-10 | 2016-06-10 | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
| PCT/US2016/044922 WO2017023818A1 (en) | 2015-07-31 | 2016-07-29 | Bacteria engineered to treat disorders involving propionate catabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521674A JP2018521674A (ja) | 2018-08-09 |
| JP2018521674A5 true JP2018521674A5 (enExample) | 2019-09-05 |
Family
ID=57944027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504991A Pending JP2018521674A (ja) | 2015-07-31 | 2016-07-29 | プロピオネート異化を伴う障害を治療するために操作された細菌 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3328988A1 (enExample) |
| JP (1) | JP2018521674A (enExample) |
| AU (1) | AU2016303662A1 (enExample) |
| CA (1) | CA2996535A1 (enExample) |
| WO (1) | WO2017023818A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3720458A4 (en) * | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| CN112143689B (zh) * | 2019-06-28 | 2023-01-03 | 中国科学院微生物研究所 | 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用 |
| CN114787344A (zh) | 2019-12-02 | 2022-07-22 | 安斯泰来制药株式会社 | 用于处置癌症的含有ny-eso-1的人工佐剂载体细胞 |
| KR20220130719A (ko) * | 2020-01-17 | 2022-09-27 | 위니베르시트카솔리끄드루뱅 | 엔벨로프 완전성이 변화된 유전자 변형 세균 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| CN104024430A (zh) * | 2011-08-26 | 2014-09-03 | 微生物诊断有限责任公司 | 用于诊断和治疗心脏缺陷的方法 |
| US20150246085A1 (en) * | 2012-11-01 | 2015-09-03 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-Modified Probiotic for Treatment of Phenylketonuria |
| WO2014138324A1 (en) | 2013-03-07 | 2014-09-12 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
-
2016
- 2016-07-29 WO PCT/US2016/044922 patent/WO2017023818A1/en not_active Ceased
- 2016-07-29 JP JP2018504991A patent/JP2018521674A/ja active Pending
- 2016-07-29 CA CA2996535A patent/CA2996535A1/en not_active Abandoned
- 2016-07-29 AU AU2016303662A patent/AU2016303662A1/en not_active Abandoned
- 2016-07-29 EP EP16751733.3A patent/EP3328988A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515106A5 (enExample) | ||
| JP2018521674A5 (enExample) | ||
| Bron et al. | Genetic characterization of the bile salt response in Lactobacillus plantarum and analysis of responsive promoters in vitro and in situ in the gastrointestinal tract | |
| Hegarty et al. | Bacteriocin production: a relatively unharnessed probiotic trait? | |
| Denou et al. | Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis | |
| Van Pijkeren et al. | Exploring optimization parameters to increase ssDNA recombineering in Lactococcus lactis and Lactobacillus reuteri | |
| Smaldone et al. | The FsrA sRNA and FbpB protein mediate the iron-dependent induction of the Bacillus subtilis lutABC iron-sulfur-containing oxidases | |
| Zhao et al. | Role of methionine sulfoxide reductases A and B of Enterococcus faecalis in oxidative stress and virulence | |
| Hemarajata et al. | Lactobacillus reuteri-specific immunoregulatory gene rsiR modulates histamine production and immunomodulation by Lactobacillus reuteri | |
| Burkholder et al. | Expression of LAP, a SecA2-dependent secretory protein, is induced under anaerobic environment | |
| Paul et al. | Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats | |
| Klotz et al. | S-layer associated proteins contribute to the adhesive and immunomodulatory properties of Lactobacillus acidophilus NCFM | |
| JP2018504919A5 (enExample) | ||
| Fleuchot et al. | Rgg-associated SHP signaling peptides mediate cross-talk in Streptococci | |
| O'Shea et al. | Production of multiple bacteriocins from a single locus by gastrointestinal strains of Lactobacillus salivarius | |
| Sun et al. | Accessing the inaccessible: molecular tools for bifidobacteria | |
| Ma et al. | Global transcriptomic analysis and function identification of malolactic enzyme pathway of Lactobacillus paracasei L9 in response to bile stress | |
| WO2014066945A1 (en) | Genetically-modified probiotic for treatment of phenylketonuria | |
| JP2022061035A (ja) | Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌 | |
| Corthier et al. | Use of luciferase genes as biosensors to study bacterial physiology in the digestive tract | |
| Hussain et al. | Generation of lactose-and protease-positive probiotic Lacticaseibacillus rhamnosus GG by conjugation with Lactococcus lactis NCDO 712 | |
| Alexander et al. | Exploiting prophage-mediated lysis for biotherapeutic release by Lactobacillus reuteri | |
| Lindenstrauß et al. | Transcriptome analysis of Enterococcus faecalis toward its adaption to surviving in the mouse intestinal tract | |
| Hays et al. | Type II fatty acid synthesis pathway and cyclopropane ring formation are dispensable during Enterococcus faecalis systemic infection | |
| Moon et al. | Secretion of recombinant pediocin PA-1 by Bifidobacterium longum, using the signal sequence for bifidobacterial α-amylase |